Clinical trials: Gastroparesis
Gastroparesis
Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers
The purpose of this study is to evaluate the safety and establish the pharmacokinetic (PK) profile of C13-URA in healthy volunteers
- Trial name
- NCT01074710
- Testing
- [2-13C] uracil
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Gastroparesis
Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance
The aims of MOT112571 are to assess the pharmacodynamic effects, safety, tolerability, pharmacokinetics, and potential therapeutic benefit of single doses of GSK962040 in critically ill patients with delayed gastric emptying and…
- Trial name
- NCT01039805
- Testing
- GSK962040 (50 mg), GSK962040 (75 mg)
- Where
- Australia
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Gastroparesis
Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.
This study will evaluate the safety, tolerability and exposure of repeat escalating oral doses of GSK962040.
- Trial name
- NCT00733551
- Testing
- GSK962040
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Gastroparesis, Diabetes Mellitus
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03
A 46-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either continue on relamorelin or placebo…
- Trial name
- NCT03420781
- Testing
- Relamorelin
- Where
- 337 sites in United States, Argentina and 24 more
- Volunteers
- 467 people
- Sponsor
- Allergan
Diabetic Gastroparesis, Idiopathic Gastroparesis
Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
The purpose of this study is to evaluate the dose-dependent effects of TAK-954 on gastric emptying time of solids in participants with diabetic or idiopathic gastroparesis assessed by scintigraphy.
- Trial name
- NCT03281577
- Testing
- TAK-954
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Takeda
Gastroparesis
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis.
- Trial name
- NCT04026997
- Testing
- CIN-102 Dose 1, CIN-102 Dose 2, CIN-102 Dose 3
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- CinDome Pharma, Inc.
Gastroparesis, Diabetes Mellitus
Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus
The purpose of this study is to evaluate the effect of TZP-102 on gastric emptying rate, gastroparesis symptoms and health-related quality of life in diabetic patients with gastroparesis.
- Trial name
- NCT00889486
- Testing
- TZP-102
- Where
- 23 sites in United States, Denmark and 4 more
- Volunteers
- 92 people
- Sponsor
- Tranzyme, Inc.
Gastroparesis
Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia
Itopride is a new compound that is already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton. It is used to treat symptoms associated with gastroparesis.
- Trial name
- NCT00370084
- Testing
- Itopride
- Where
- Australia
- Volunteers
- 25 people
- Sponsor
- Forest Laboratories
Gastroparesis
GEBT Telehealth Administration Usability Study
The purpose of this study is to establish the usability of a telehealth platform for the administration of GEBT.
- Trial name
- NCT04684992
- Testing
- GEBT Telehealth Administration Usability
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Cairn Diagnostics
Gastroparesis, Gastroparesis Nondiabetic
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
The purpose of this research study is to evaluate if an enhanced Enterra device programming strategy will improve symptoms associated with gastroparesis, improve symptoms in a faster amount of time, and improve quality of life…
- Conditions
- Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
- Trial name
- EXPEDITE (NCT06560307)
- Testing
- Enterra Therapy System
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Enterra Medical, Inc.
Idiopathic Gastroparesis
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects.
- Trial name
- NCT06899217
- Testing
- CIN-102 Dose 15mg, CIN-102 Dose 10mg
- Where
- 85 sites in United States
- Volunteers
- 416 people
- Sponsor
- CinDome Pharma, Inc.
Gastroparesis, Diabetes Mellitus
Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic Gastroparesis
The purpose of this study is to determine whether TZP-101 is safe in people with diabetes. Also to determine if TZP-101 is effective in increasing the gastric emptying rate in diabetic patients.
- Trial name
- NCT00639808
- Testing
- 5% dextrose in water, TZP-101
- Where
- 3 sites in Denmark, Sweden
- Volunteers
- 10 people
- Sponsor
- Tranzyme, Inc.
Diabetic Gastroparesis
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis
The purpose of this study is evaluate the safety and efficacy of Metoclopramide Nasal Spray compared to placebo in reducing the symptoms of diabetic gastroparesis in adult men.
- Trial name
- NCT02025751
- Testing
- Metoclopramide Nasal Spray
- Where
- 49 sites in United States
- Volunteers
- 53 people
- Sponsor
- Evoke Pharma